4-(5-chloropyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)benzamide | 1072066-02-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(5-chloropyridin-2-yloxy)-N-(5-hydroxy-adamantan-2-yl)benzamide
• 英文别名: 4-(5-chloropyridin-2-yl)oxy-N-(5-hydroxy-2-adamantyl)benzamide
• CAS: 1072066-02-4
• 化学式: C₂₂H₂₃ClN₂O₃
• 分子量: 398.889
• InChiKey: WPOKSAJCUSLHGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• NOVEL COMPOUNDS
  申请人：High Point Pharmaceuticals, LLC

  公开号：EP2152081A1

  公开（公告）日：2010-02-17
• 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF
  申请人：Jacobson Peer B.

  公开号：US20110159005A1

  公开（公告）日：2011-06-30

  A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme.
• US8871208B2
  申请人：——

  公开号：US8871208B2

  公开（公告）日：2014-10-28
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：TRANSTECH PHARMA INC

  公开号：WO2008127924A1

  公开（公告）日：2008-10-23

  [EN] Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11ß -hydroxysteroid dehydrogenase type 1 (11ßHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.
  [FR] L'invention concerne de nouveaux inhibiteurs à base de benzamide substitué, leur emploi dans des thérapies, des compositions pharmaceutiques comprenant ces composés, l'utilisation desdits composés lors de la fabrication de médicaments, et des procédés thérapeutiques incluant l'administration desdits composés. Les composés selon l'invention modulent l'activité de la 11ß-hydroxystéroïde déshydrogénase de type 1 (11ßHSD1), et sont donc utiles pour traiter les maladies dans lesquelles une telle modulation est bénéfique, comme le syndrome métabolique, par exemple.